Phaseline

Companies › Shanghai Guangsheng Biopharmaceutical

Shanghai Guangsheng Biopharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cosiporfin Sodium for Injection (DVDMS)
Photosensitizer; generates reactive oxygen species upon light activation for photodynamic
–Phase 2Biliary Tract Cancers (BTC)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07398339Cosiporfin Sodium for Injection (DVDMS)Phase 2Biliary Tract Cancers (BTC)OncologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics Zenith Epigenetics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.